See more : Villars Holding S.A. (0QLJ.L) Income Statement Analysis – Financial Results
Complete financial analysis of Amryt Pharma plc (AMYT) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Amryt Pharma plc, a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
- Bel Fuse Inc. (BELFB) Income Statement Analysis – Financial Results
- China Telecom Corporation Limited (0728.HK) Income Statement Analysis – Financial Results
- Chabiotech Co.,Ltd. (085660.KQ) Income Statement Analysis – Financial Results
- Brioschi Sviluppo Immobiliare S.p.A. (BRI.MI) Income Statement Analysis – Financial Results
- Terns Pharmaceuticals, Inc. (TERN) Income Statement Analysis – Financial Results
Amryt Pharma plc (AMYT)
Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Website: https://www.amrytpharma.com
About Amryt Pharma plc
Amryt Pharma plc, a commercial-stage biopharmaceutical company, focuses on acquiring, developing, and commercializing various treatments to help improve the lives of patients with rare and orphan diseases. The company provides metreleptin, an adjunct to diet as replacement therapy to treat the complications of leptin deficiency in patients with congenital or acquired generalized lipodystrophy; oral octreotide, a long-term maintenance therapy in acromegaly patients; and lomitapide, an adjunct to a low-fat diet and other lipid-lowering medicinal products for adults with the Homozygous familial Hypercholesteraemia. Its development candidates include Oleogel-S10 for the cutaneous manifestations of Junctional and Dystrophic Epidermolysis Bullosa (EB), a rare and distressing genetic skin disorder affecting young children and adults; and AP103, a pre-clinical gene therapy for patients with dystrophic EB. The company sells its products in the Americas, Europe, and the Middle East. Amryt Pharma plc was founded in 2015 and is headquartered in Dublin, Ireland.
| Metric | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 222.54M | 182.61M | 58.12M | 16.53M | 15.33M | 1.42M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 106.12M | 119.03M | 42.00M | 6.06M | 6.45M | 616.30K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 116.42M | 63.58M | 16.12M | 10.47M | 8.88M | 804.55K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 52.32% | 34.82% | 27.74% | 63.35% | 57.95% | 56.62% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 37.73M | 27.62M | 15.83M | 10.35M | 12.67M | 2.47M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 8.34M | 4.73M | 841.00K | 17.57M | 13.25M | 4.25M | 3.33M | 2.93M | 1.87M | 275.37K | 281.22K | 1.72M | 1.74M | 3.05M | 2.33M |
| Selling & Marketing | 92.00M | 76.67M | 35.50M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 100.34M | 81.40M | 36.34M | 17.57M | 13.25M | 4.25M | 3.33M | 2.93M | 1.87M | 275.37K | 281.22K | 1.72M | 1.74M | 3.05M | 2.33M |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -80.83K | -47.51K | 5.03K | 11.50K |
| Operating Expenses | 138.07M | 109.02M | 52.17M | 27.92M | 25.93M | 6.95M | 3.34M | 2.93M | 1.86M | 275.37K | 281.22K | 281.82K | 1.74M | 3.05M | 2.33M |
| Cost & Expenses | 244.18M | 228.05M | 94.17M | 33.98M | 32.37M | 7.57M | 3.34M | 2.93M | 1.86M | 275.37K | 281.22K | 281.82K | 1.74M | 3.05M | 2.33M |
| Interest Income | 5.00K | 87.00K | 92.00K | 5.72K | 6.00K | 1.05K | 185.00K | 201.00K | 319.07K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 27.91M | 19.57M | 8.48M | 1.78M | 989.75K | 127.26K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 50.74M | 44.47M | 12.63M | 354.61K | 310.72K | 204.03K | 6.00K | 6.00K | 4.56K | 0.00 | 99.63K | 147.69K | 144.69K | 224.23K | 161.09K |
| EBITDA | 29.10M | -977.00K | -23.42M | -17.09M | -16.73M | -5.94M | 33.26M | -3.10M | -1.27M | -275.37K | -281.22K | -281.82K | -1.60M | -2.83M | -2.17M |
| EBITDA Ratio | 13.08% | -0.54% | -40.29% | -103.36% | -109.16% | -418.28% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -21.64M | -45.44M | -36.04M | -17.44M | -17.04M | -8.08M | -39.93M | -2.93M | -3.51M | -275.37K | -281.22K | -281.82K | -459.87K | -3.28M | -2.43M |
| Operating Income Ratio | -9.72% | -24.89% | -62.01% | -105.51% | -111.18% | -568.69% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -8.17M | -60.42M | -30.72M | -12.00M | -14.31M | -127.26K | 189.00K | -36.81M | 376.00K | -1.84M | -5.85K | 0.00 | -63.03K | 7.94K | 14.28K |
| Income Before Tax | -29.81M | -105.86M | -66.76M | -29.45M | -31.36M | -8.21M | -39.74M | -2.56M | -2.12M | -275.37K | -281.22K | -281.82K | -522.90K | -3.27M | -2.41M |
| Income Before Tax Ratio | -13.40% | -57.97% | -114.86% | -178.09% | -204.54% | -577.65% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | -11.64M | -1.33M | -1.23M | 41.18K | 14.31M | 1.93M | 73.18M | -175.00K | 2.23M | 550.74K | 2.68M | 1.51K | -25.79K | 226.22K | 101.27K |
| Net Income | -18.17M | -104.53M | -65.54M | -29.49M | -45.67M | -8.21M | -39.74M | -2.56M | -2.12M | -826.12K | -3.06M | -123.58K | -497.11K | -3.27M | -2.41M |
| Net Income Ratio | -8.17% | -57.24% | -112.75% | -178.34% | -297.89% | -577.65% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -0.39 | -2.92 | -4.32 | -3.22 | -6.14 | -1.51 | -3.45 | -0.26 | -0.33 | -0.08 | -0.30 | -0.01 | -0.05 | -0.42 | 0.00 |
| EPS Diluted | -0.37 | -2.92 | -4.32 | -3.22 | -6.14 | -1.51 | -3.45 | -0.26 | -0.33 | -0.08 | -0.30 | -0.01 | -0.05 | -0.42 | 0.00 |
| Weighted Avg Shares Out | 47.17M | 35.76M | 15.17M | 9.16M | 7.44M | 5.44M | 11.51M | 9.81M | 6.47M | 10.12M | 10.12M | 10.12M | 9.59M | 7.87M | 0.00 |
| Weighted Avg Shares Out (Dil) | 49.40M | 35.76M | 15.17M | 9.16M | 7.44M | 5.44M | 11.51M | 9.81M | 6.47M | 10.12M | 10.12M | 10.12M | 9.59M | 7.87M | 0.00 |
Amryt Pharma ups guidance after record second quarter
Amryt Reports Record Q2 2021 Results and Raises FY 2021 Guidance
Amryt Pharma advancing on multiple fronts
Amryt Pharma completes Chiasma acquisition
Result of General Meetings
Amryt to Report Q2 2021 Results and Host Conference Call & Webcast on August 6
Publication of Circular to Amryt Shareholders in relation to the acquisition of Chiasma, Inc., and posting of Annual Report and Notices of General Meetings
Amryt Pharma Announces Filing of Preliminary Registration Statement on Form F-4 in Connection with Its Proposed Acquisition of Chiasma, Inc.
Amryt Pharma Oleogel-S10 appllcation won't go through advisory committee
FDA confirms NDA for Oleogel-S10 will not require an Advisory Committee Meeting
Source: https://incomestatements.info
Category: Stock Reports